

Income statement

Three months ended 31st March 2009

	Total Q1 2009 £m	Total Q1 2008 £m	Growth	
			CER%	£%
TURNOVER	6,769	5,686	(5)	19
Cost of sales	(1,787)	(1,359)	17	31
Gross profit	4,982	4,327	(12)	15
Selling, general and administration	(2,200)	(1,745)	(1)	26
Research and development	(1,124)	(780)	20	44
Other operating income	54	161		
OPERATING PROFIT	1,712	1,963	(40)	(13)
Finance income	28	82		
Finance expense	(203)	(170)		
Profit on disposal of interest in associate	115			
Share of after tax profits of associates and joint ventures	14	(1)		
PROFIT BEFORE TAXATION	1,666	1,874	(40)	(11)
Taxation	(497)	(542)		
<i>Tax rate %</i>	29.8%	28.9%		
PROFIT AFTER TAXATION FOR THE PERIOD	1,169	1,332	(41)	(12)
Profit attributable to minority interests	38	25		
Profit attributable to shareholders	1,131	1,307		
	1,169	1,332		
EARNINGS PER SHARE	22.3p	24.4p	(39)	(9)
Diluted earnings per share	22.2p	24.2p		

Pharmaceuticals turnover

Three months ended 31st March 2009

	Total			USA			Europe			Rest of World		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
Respiratory	1,735	1	28	844	(1)	37	546	(1)	12	345	9	36
<i>Avamys/Veramyst</i>	31	85	>100	20	17	67	9	>100	>100	2	-	-
<i>Flixonase/Flonase</i>	69	11	50	10	100	>100	12	(23)	(8)	47	14	62
<i>Flixotide/Flovent</i>	195	(6)	20	99	(4)	32	48	(2)	9	48	(12)	12
<i>Seretide/Advair</i>	1,214	-	27	653	(5)	31	394	-	14	167	26	52
<i>Serevent</i>	62	(24)	(7)	19	(18)	12	31	(22)	(16)	12	(38)	(8)
<i>Ventolin</i>	116	23	51	38	>100	>100	37	(3)	12	41	(5)	11
<i>Zyrtec</i>	18	9	64	-	-	-	-	-	-	18	9	64
Anti-virals	1,116	18	51	488	2	41	340	45	63	288	16	57
HIV	419	(8)	17	195	(8)	28	169	(9)	8	55	(6)	12
<i>Agenerase, Lexiva</i>	48	6	37	27	6	50	17	(7)	13	4	100	100
<i>Combivir</i>	112	(16)	7	53	(16)	18	41	(17)	(2)	18	(17)	-
<i>Epivir</i>	34	(21)	-	13	(18)	18	14	(20)	(7)	7	(25)	(13)
<i>Epzicom/Kivexa</i>	137	10	38	58	5	45	62	10	29	17	27	55
<i>Trizivir</i>	56	(20)	4	30	(22)	11	24	(17)	-	2	(33)	(33)
<i>Ziagen</i>	27	(16)	8	14	-	40	9	(11)	-	4	(50)	(33)
<i>Valtrex</i>	344	2	38	257	8	49	42	-	20	45	(17)	10
<i>Relenza</i>	222	>100	>100	11	-	38	110	-	-	101	>100	>100
<i>Zeffix</i>	53	(13)	15	4	-	33	7	(14)	-	42	(14)	17
Central Nervous System	499	(53)	(40)	216	(73)	(64)	145	(2)	12	138	(3)	30
<i>Imigran/Imitrex</i>	64	(68)	(61)	28	(83)	(79)	25	(4)	9	11	-	38
<i>Lamictal</i>	144	(61)	(50)	86	(74)	(64)	39	3	18	19	-	12
<i>Requip</i>	50	(56)	(47)	8	(90)	(87)	32	(3)	10	10	40	100
<i>Requip XL</i>	22	>100	>100	5	-	-	17	>100	>100	-	-	-
<i>Seroxat/Paxil</i>	126	(21)	4	14	(61)	(55)	28	(14)	-	84	(3)	35
<i>Treximet</i>	14	-	-	14	-	-	-	-	-	-	-	-
<i>Wellbutrin, Wellbutrin XL</i>	64	(63)	(49)	54	(68)	(55)	6	67	100	4	50	100
Cardiovascular and	551	6	38	344	7	48	141	2	22	66	10	32
<i>Arixtra</i>	59	29	69	33	26	74	22	29	57	4	50	100
<i>Avodart</i>	122	12	44	73	8	49	36	7	29	13	50	63
<i>Coreg, Coreg CR</i>	51	(23)	6	51	(23)	6	-	-	-	-	-	-
<i>Fraxiparine</i>	55	(8)	8	-	-	-	43	(10)	5	12	-	20
<i>Levitra</i>	20	7	43	19	8	46	1	-	-	-	-	-
<i>Lovaza</i>	106	54	>100	105	52	>100	-	-	-	1	-	-
<i>Vesicare</i>	24	21	71	24	21	71	-	-	-	-	-	-
<i>Volibris</i>	2	-	-	-	-	-	2	-	-	-	-	-
Metabolic	294	(16)	8	150	(18)	13	68	(21)	(7)	76	(8)	15
<i>Avandia products</i>	197	(19)	3	112	(18)	13	43	(30)	(20)	42	(8)	11
<i>Avandia</i>	121	(23)	(1)	74	(25)	4	18	(27)	(18)	29	(14)	-
<i>Avandamet</i>	66	(16)	6	31	(4)	29	24	(32)	(23)	11	14	57
<i>Bonvival/Boniva</i>	62	(4)	27	38	(15)	15	21	20	40	3	-	>100
Anti-bacterials	426	(1)	17	47	(24)	4	189	(7)	8	190	13	33
<i>Augmentin</i>	186	-	19	16	(29)	(6)	84	(9)	6	86	20	43
Oncology and emesis	144	1	27	70	(12)	21	51	16	38	23	11	28
<i>Hycamtin</i>	43	10	43	26	6	53	15	9	36	2	50	-
<i>Promacta</i>	2	-	-	2	-	-	-	-	-	-	-	-
<i>Tyverb/Tykerb</i>	34	42	79	11	(20)	10	17	>100	>100	6	100	>100
<i>Zofran</i>	32	(7)	10	7	67	>100	14	(25)	(13)	11	-	10
Vaccines	625	18	43	119	(21)	9	286	23	43	220	46	73
<i>Boostrix</i>	26	62	100	11	60	>100	8	40	60	7	100	>100
<i>Cervarix</i>	48	>100	>100	-	-	-	39	>100	>100	9	>100	>100
<i>Fluarix, FluLaval</i>	6	-	-	-	-	-	-	-	-	6	-	-
<i>Flu Pre-Pandemic</i>	6	20	20	-	-	-	5	25	25	1	-	-
<i>Hepatitis</i>	149	(12)	7	52	(28)	(2)	61	(5)	9	36	3	20
<i>Infanrix, Pediarix</i>	175	(5)	14	39	(41)	(24)	109	14	35	27	14	29
<i>Rotarix</i>	57	74	>100	15	-	-	13	22	44	29	39	61
Other	233	(25)	(11)	5	-	25	74	(7)	4	154	(32)	(18)
	5.623	(6)	18	2.283	(22)	7	1.840	7	23	1.500	6	32

Pharmaceutical turnover includes co-promotion income

Consumer Healthcare turnover

Three months ended 31st March 2009

	Total			USA			Europe			Rest of World		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
Over-the-counter	567	5	30	180	4	44	156	(2)	8	231	13	38
<i>alli</i>	32	>100	>100	29	>100	>100	3	-	-	-	-	(100)
<i>Breathe Right</i>	27	24	59	14	11	56	7	20	40	6	67	100
Cold sore franchise	23	(5)	15	9	-	29	11	(10)	10	3	-	-
Nicotene replacement	82	12	41	58	11	53	17	6	6	7	50	75
<i>Panadol</i>	99	6	24	-	-	-	20	(11)	5	79	11	30
<i>Tums</i>	30	5	43	27	6	50	-	-	-	3	-	-
Oral healthcare	368	5	27	78	14	56	184	1	16	106	8	33
<i>Aquafresh</i> franchise	128	-	20	27	(5)	35	73	(2)	14	28	9	22
<i>Biotene</i>	6	-	-	5	-	-	-	-	-	1	-	-
Denture care	80	5	33	19	-	36	28	-	17	33	14	50
<i>Sensodyne</i> franchise	112	7	30	26	27	73	47	2	15	39	3	30
Nutritional healthcare	211	1	9	-	-	-	95	(15)	(14)	116	22	40
<i>Horlicks</i>	75	20	34	-	-	-	5	(17)	(17)	70	24	40
<i>Lucozade</i>	80	(12)	(7)	-	-	-	65	(16)	(14)	15	20	50
<i>Ribena</i>	38	(5)	3	-	-	-	25	(7)	(7)	13	-	30
	1,146	4	25	258	7	47	435	(4)	5	453	14	37